Skip to content
Site Tools
Narrow screen resolution Wide screen resolution Auto-adjust screen resolution Increase font size Decrease font size Default font size
You are here: Home arrow Books arrow Proteomics arrow Cancer Proteomics: From Bench to Bedside (2007)
Cancer Proteomics: From Bench to Bedside (2007) PDF Print E-mail
User Rating: / 1
PoorBest 
Written by bioXplorer   
Dec 28, 2007 at 09:35 AM
Image

Title: Cancer Proteomics: From Bench to Bedside

Author(s): Sayed S. Daoud

Series: Cancer Drug Discovery and Development

Publisher: Humana Press

ISBN: 1588298582

Publication: 2007

Pages: 300

Description: This book provides the reader with broad perspectives and breadth of knowledge on current topics related to the use of proteomic strategies in cancer therapy as well as anticipated challenges that may arise from its application in daily practice. The book is divided into 4 parts. The first part begins with the current technologies used in proteomics that allow for protein profiling and for the identification of druggable targets in human samples. Mass spectrometry based protein characterization and protein microarrays hold great promise of predicting response to specific drugs in cancer therapy. The second part deals with the use proteomics in cell signaling. At the present, the pharmaceutical and biotechnology industries have many potentially useful small molecule inhibitors of many pathways important in cancer that have yet to be taken to clinical trials. Understanding protein-protein interaction and posttranslational modifications through proteomics will likely make it much more feasible to do effective clinical trials of these small molecules alone and in combinations to overcome drug resistance and improve patient care. The third part of the book moves from signaling to actual clinical applications of proteomics in cancer therapy. Case studies in may tumor types are provided to show the feasibility of generating the critical information needed to individualization of therapy in cancer patients. The final part of the book provides in depth information on annotating the human proteome and the role of Food and Drug Administration (FDA) in regulating the use of proteomics in cancer therapy. To functionally annotate the human proteome, the Swiss Institute for Bioinformatics (SIB) and the European Bioinformatics Institute (EBI) initiated a major effort to distribute to the scientific community highly integrated information on human protein sequences. This initiative, which is called the Human Proteomics Initiative (HPI) aims to provide for each known human protein a wealth of information that include the description of its function, domain and protein family classification, subcellular location, posttranslational modifications, variants and similarities to other proteins. Integration of bioinformatics into clinical application of proteomics in cancer therapy is outlined as well as regulations and policy of commercial application of proteomics in patient care.

Download (3.5 MB):

Must be registered to view link!


Add as favourites (1) | Views: 748

  Comments (1)
 1 Written by chatsurachai, on 15-05-2008 04:20
Thank you very much :)

Only registered users can write comments.
Please login or register.

Powered by AkoComment Tweaked Special Edition v.1.4.6
AkoComment © Copyright 2004 by Arthur Konze - www.mamboportal.com
All right reserved

Recomended Sites

Who's Online

We have 117 guests online and 9 members online

Login

Username

Password

Remember me
Password Reminder
No account yet? Create one